The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Modulation of plasma cytokines and its association with clinical response to treatment with the JAK2-selective inhibitor SAR302503 in myelofibrosis (MF).
Moshe Talpaz
Consultant or Advisory Role - ARIAD
Research Funding - ARIAD
Catriona H. M. Jamieson
Consultant or Advisory Role - Janssen; Novartis; Sanofi
Nashat Y. Gabrail
Research Funding - Sanofi
Claudia Lebedinsky
Employment or Leadership Position - Sanofi
Feng Liu
Employment or Leadership Position - Sanofi
Hui Cao
Employment or Leadership Position - Sanofi
Ayalew Tefferi
No relevant relationships to disclose
Animesh Dev Pardanani
Research Funding - Bristol-Myers Squibb; Sanofi ; YM BioSciences